Format

Send to

Choose Destination
See comment in PubMed Commons below
J Infect Dis. 2011 Feb 15;203(4):473-8. doi: 10.1093/infdis/jiq077. Epub 2011 Jan 13.

A therapeutic dendritic cell-based vaccine for HIV-1 infection.

Author information

1
Infectious Diseases Department, Hospital Clinic - HIV Development Program in Catalonia, Institut d'Investigacions Biomédiques August Pi I Sunyer, University of Barcelona, Spain. fgarcia@clinic.ub.es

Abstract

A double-blinded, controlled study of vaccination of untreated patients with chronic human immunodeficiency virus type 1 (HIV-1) infection with 3 doses of autologous monocyte-derived dendritic cells (MD-DCs) pulsed with heat inactivated autologous HIV-1 was performed. Therapeutic vaccinations were feasible, safe, and well tolerated. At week 24 after first vaccination (primary end point), a modest significant decrease in plasma viral load was observed in vaccine recipients, compared with control subjects (P = .03). In addition, the change in plasma viral load after vaccination tended to be inversely associated with the increase in HIV-specific T cell responses in vaccinated patients but tended to be directly correlated with HIV-specific T cell responses in control subjects.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT00402142.

PMID:
21233310
PMCID:
PMC3071229
DOI:
10.1093/infdis/jiq077
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems Icon for PubMed Central
    Loading ...
    Support Center